In recent years, a lot of pharmaceutical companies have developed various PTP1B inhibitors as drug candidates for therapy of T2D in clinical trials, including ertiprotafib, ISIS 113715 and MSI1436-trodusquemine. The gene discussed is PTPN1; the disease is type 2 diabetes mellitus.